NCT06076486View on ClinicalTrials.gov

A Clinical Trial to Evaluate Efficacy and Safety of Elagolix Tablets in Women With Moderate or Severe Endometriosis-associated Pain

PHASE3CompletedINTERVENTIONAL
Enrollment

202

Participants

Timeline

Start Date

September 14, 2023

Primary Completion Date

November 22, 2024

Study Completion Date

April 2, 2025

Conditions
Endometriosis
Interventions
DRUG

Elagolix

Elagolix 200 mg tablets administered orally BID

DRUG

Elagolix placebo

Elagolix placebo administered orally BID

Trial Locations (1)

100034

Peking University First Hospital, Beijing

Sponsors
All Listed Sponsors
lead

Nanjing Chia-tai Tianqing Pharmaceutical

INDUSTRY